Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal
SNY•Sanofi will pay Regeneron $1 billion upfront and up to $7 billion in milestone payments to add four long-acting immunology antibodies to their partnership. The companies will split costs and profits equally and have settled earlier litigation over the collaboration.
1. Expanded partnership
Sanofi said it would pay Regeneron $1 billion upfront and up to $7 billion more in milestone payments to add four next-generation, long-acting immunology antibodies to the partnership behind Dupixent. The companies said they had settled earlier litigation over the collaboration and would split costs and profits equally.
